KVUE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Kenvue Inc (KVUE) is not a strong buy at this moment for a beginner investor with a long-term strategy. The stock shows limited upside potential based on analyst ratings, and there are legal risks associated with ongoing litigation. While the company has demonstrated solid financial performance in the latest quarter, the lack of strong trading signals and mixed sentiment from analysts suggest that holding off on buying is prudent for now.
The MACD is above zero and positively contracting, indicating a mild bullish trend, but RSI is neutral at 66.037, suggesting no clear momentum. Moving averages are converging, and the stock is trading near its resistance level of 19.009, which may limit immediate upside potential.
The company's Q4 financials showed YoY growth in revenue (+3.22%), net income (+12.63%), and EPS (+13.33%). Analyst upgrades from Canaccord, UBS, and Citi with slight increases in price targets reflect some optimism. Kimberly-Clark's acquisition of Kenvue is expected to enhance long-term growth prospects.
A Texas judge rejected Kenvue's attempt to dismiss a lawsuit alleging risks of autism and ADHD linked to Tylenol use during pregnancy, creating legal uncertainty. Jefferies downgraded the stock to Hold, citing limited upside and litigation risks. Gross margin dropped slightly (-0.37% YoY), and hedge funds and insiders show no significant trading activity.
In Q4 2025, Kenvue reported revenue growth of 3.22% YoY to $3.78 billion, net income growth of 12.63% YoY to $330 million, and EPS growth of 13.33% YoY to $0.17. However, gross margin decreased slightly to 56.53% (-0.37% YoY).
Recent analyst ratings are mixed. Canaccord, UBS, and Citi raised price targets to $18, $19, and $20, respectively, but maintain Hold or Neutral ratings. Jefferies downgraded the stock to Hold with a price target of $18, citing litigation risks and limited upside potential.
